The United States of America, As Represented by the Secretary, Department of Health and Human Services

New York Blood Center, Inc.

Other

Columbia University

Sanofi

Young Do Kwon

Peter D Kwong

Asim Kumar Debnath

Francesca Curreli

John R Mascola

Baoshan Zhang

Ivelin Georgiev

Gwo-Yu Chuang

Mark Connors

Xueling Wu

Gary J Nabel

Yongping Yang

Wei Shi

John Mascola

Amos B Smith, Iii

Huawei Qiu

Tongqing Zhou

Zhi-yong Yang

Joseph G Sodroski

Ercole Rao

Christian Lange

Rebecca S Rudicell

Richard Schwartz

Gilad Ofek

Mark Louder

David Michael Jones

Jochen Kruip

Robert Bailer

Ernesto Freire

Christian Beil

Ling Xu

Zhi-Yong Yang

Joel R Courter

Jochen Beninga

Wulf Dirk Leuschner

Jiang Zhu

Jinghe Huang

Lawrence Shapiro

Mangaiarkarasi Asokan

Jonathan Cooper

Kevin Carlton

Michael Bender

Krisha McKee

Amarendra Pegu

Tatyana Gindin

Lisa Kueltzo

Sijy O'Dell

Wayne A Hendrickson

Navid Madani

Judith M LaLonde

Amy M Princiotto

Alexander W Sun

Arne Schön

Takahiro Soeta

Matthew Le-Khac

Paolo Lusso

Toyoharu Kobayashi

Jongwoo Park

Richard A Koup

Qingbo Liu

Nicole A Doria-rose

Ronnie Wei

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

Neutralizing antibodies to HIV-1 Env and their use

Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV

Neutralizing antibodies to HIV-1 GP41 and their use

Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.

Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein

Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein

Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.

CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof

Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses.

HIV inhibitors

An electrodeless fluorescent light source that includes a non-conducting light transmissive hermetically sealed envelope containing an ionizable gas which is electromagnetically coupled to an ionizing radio frequency (r.f.) energy source is described. The r.f. energy source is an induction coil wound in the form of a toroidal helix to minimize microwave radiation leakage, and is placed within the envelope and in direct contact with the gas in order to maximize energy coupling to the gas.

Electrodeless fluorescent lamp

Growing community of inventors

Bethesda, MD, United States of America

Young Do Kwon